AEM vs FNV

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

Franco-Nevada exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a massive current ratio of 8.30, indicating a fortress balance sheet. While the stock trades at a significant premium to its Graham Number ($71.7) and Intrinsic Value ($170.21), this is supported by explosive YoY revenue growth of 85.8% and earnings growth of 108.8%. The company's royalty-based model is reflected in its extraordinary profit margins (61.64%), though current technical trends are bearish. Long-term value is driven by consistent earnings beats and a strong analyst target of $306.36. Price trades at a 28.6% premium to fair value estimate ($188.50), limiting near-term upside from a valuation perspective.